Literature DB >> 1311195

Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia.

M H Freedman1, A Cohen, T Grunberger, N Bunin, R E Luddy, E F Saunders, N Shahidi, A Lau, Z Estrov.   

Abstract

In previous studies on patients with juvenile chronic myelogenous leukaemia (JCML), we found excessive proliferation of malignant monocyte-macrophage elements in the absence of exogenous growth factor, and impaired growth of normal haematopoietic progenitors. In the current study, six newly-diagnosed JCML patients were investigated to characterize the disease further. In co-cultures, JCML cell culture supernatant as well as patient plasma obtained at diagnosis produced a striking reduction in numbers of control marrow BFU-E, CFU-GM, CFU-Meg and CFU-GEMM colonies. Monoclonal anti-tumour necrosis factor alpha neutralizing antibodies (anti-TNF-alpha Ab) abolished these inhibitory properties. In sharp contrast, JCML supernatants exerted a marked growth-promoting effect on autologous JCML cells cultured in clonogenic assays. Anti-TNF-alpha Ab and anti-granulocyte-macrophage colony-stimulating factor neutralizing antibodies (anti-GM-CSF Ab) both reversed the stimulating effect. Recombinant GM-CSF and recombinant TNF alpha produced a profound increase in JCML colonies when tested individually and anti-GM-CSF Ab reversed the TNF-alpha effect. Expression studies of TNF-alpha and TNF-alpha receptor genes of cultured JCML cells demonstrated mRNAs for both. Further, TNF-alpha activity was assayed in a wide variety of cell culture supernatants and in normal and patients' plasma, and only the JCML specimens showed increased TNF-alpha values. Recombinant interleukin-1 alpha (IL-1 alpha) also stimulated JCML colony growth, but polyclonal anti-IL-1 neutralizing antibodies did not suppress JCML colony numbers nor did it reverse the effects of TNF-alpha or GM-CSF. The evidence indicated that the JCML monokine which inhibits normal haematopoiesis is TNF-alpha and that the endogenously-produced TNF-alpha and GM-CSF from JCML cells play an important role in the pathogenesis of the disease by acting as autocrine growth factors. IL-1 alpha also stimulates JCML cell proliferation as an accessory factor and augments the effect of GM-CSF, TNF-alpha or both.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311195     DOI: 10.1111/j.1365-2141.1992.tb06398.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.

Authors:  Rebecca J Chan; Todd Cooper; Christian P Kratz; Brian Weiss; Mignon L Loh
Journal:  Leuk Res       Date:  2008-10-26       Impact factor: 3.156

2.  Deoxyribonucleic acid triplex formation inhibits granulocyte macrophage colony-stimulating factor gene expression and suppresses growth in juvenile myelomonocytic leukemic cells.

Authors:  M Kochetkova; P O Iversen; A F Lopez; M F Shannon
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

3.  Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.

Authors:  Thomas Wilhelm; Daniel B Lipka; Tania Witte; Justyna A Wierzbinska; Silvia Fluhr; Monika Helf; Oliver Mücke; Rainer Claus; Carolin Konermann; Peter Nöllke; Charlotte M Niemeyer; Christian Flotho; Christoph Plass
Journal:  Epigenetics       Date:  2016-02-18       Impact factor: 4.528

4.  Long-term serial xenotransplantation of juvenile myelomonocytic leukemia recapitulates human disease in Rag2-/-γc-/- mice.

Authors:  Christopher Felix Krombholz; Konrad Aumann; Matthias Kollek; Daniela Bertele; Silvia Fluhr; Mirjam Kunze; Charlotte M Niemeyer; Christian Flotho; Miriam Erlacher
Journal:  Haematologica       Date:  2016-02-17       Impact factor: 9.941

5.  Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.

Authors:  Zhenyun Yang; Takako Kondo; Cara S Voorhorst; Sarah C Nabinger; Leila Ndong; Fuqin Yin; Edward M Chan; Menggang Yu; Oliver Würstlin; Christian P Kratz; Charlotte M Niemeyer; Christian Flotho; Eri Hashino; Rebecca J Chan
Journal:  Mol Cell Biol       Date:  2009-06-15       Impact factor: 4.272

6.  Molecular targets for the treatment of juvenile myelomonocytic leukemia.

Authors:  Xiaoling Liu; Himalee Sabnis; Kevin D Bunting; Cheng-Kui Qu
Journal:  Adv Hematol       Date:  2011-11-13

7.  The safety of etanercept for the treatment of plaque psoriasis.

Authors:  Kim A Papp
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

8.  Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines.

Authors:  Y Y Zhang; T A Vik; J W Ryder; E F Srour; T Jacks; K Shannon; D W Clapp
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

9.  Concurrent juvenile myelomonocytic leukemia with thalassemia in a case with Plasmodium knowlesi infection from Sabah, Malaysian Borneo.

Authors:  Mimi Azreen Abdullah; Saleh Mohammed Abdullah; Subbiah Vijay Kumar; Mohammad Zahirul Hoque
Journal:  Hematol Rep       Date:  2019-06-24

Review 10.  Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy.

Authors:  María Florencia Mercogliano; Sofía Bruni; Florencia Mauro; Patricia Virginia Elizalde; Roxana Schillaci
Journal:  Cancers (Basel)       Date:  2021-02-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.